<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0186-4866</journal-id>
<journal-title><![CDATA[Medicina interna de México]]></journal-title>
<abbrev-journal-title><![CDATA[Med. interna Méx.]]></abbrev-journal-title>
<issn>0186-4866</issn>
<publisher>
<publisher-name><![CDATA[Edición y Farmacia S.A. de C.V.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0186-48662017000300363</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Inhibidores del cotransportador de sodio y glucosa tipo 2 (SGLT2), el riñón como objetivo en el control glucémico de la diabetes mellitus tipo 2]]></article-title>
<article-title xml:lang="en"><![CDATA[Sodium-glucose co-transporter 2 (SGLT2) inhibitors, kidney as objective in the glycemic control of diabetes mellitus type 2.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Hernández]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,ISEM Hospital General de Ecatepec Dr. José María Rodríguez ]]></institution>
<addr-line><![CDATA[ Estado de México]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<volume>33</volume>
<numero>3</numero>
<fpage>363</fpage>
<lpage>371</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0186-48662017000300363&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0186-48662017000300363&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0186-48662017000300363&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La diabetes mellitus tipo 2 es una de las enfermedades crónicas más graves y prevalentes a la fecha, y constituye una causa muy importante de morbilidad y mortalidad en el mundo. A pesar del gran número de fármacos que existen para el control de la diabetes muchas personas con esta afección no logran un buen control de las cifras de glucosa. La hiperglucemia es el blanco terapéutico primordial en el tratamiento de la diabetes mellitus tipo 2, y se han desarrollado múltiples familias de fármacos para lograr el control glucémico que evite complicaciones a corto y largo plazos. Los inhibidores del cotransportador de sodio y glucosa tipo 2 (SGLT2) son una nueva familia de fármacos que reducen la reabsorción renal de glucosa e incrementan su eliminación urinaria, disminuyendo las concentraciones de glucosa.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Type 2 diabetes is the most important and prevalent chronic disease today, being an important morbidity and mortality cause worldwide. Despite the great number of medications for diabetes control, many people with this condition do not achieve good glycemic control. Hyperglycemia is the key therapeutic focus in diabetes mellitus management, with many drug families developed to the date for get the target glucose level for prevent the acute and long term complications of this disease. Sodium glucose co-transporter type 2 inhibitors (SGLT2) are a new drug family that reduce renal glucose reabsorption and increase the urinary glucose elimination, thus lowering the blood glucose levels.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[fármacos contra la diabetes]]></kwd>
<kwd lng="es"><![CDATA[diabetes mellitus tipo 2]]></kwd>
<kwd lng="es"><![CDATA[inhibidores del cotransportador de sodio y glucosa tipo 2]]></kwd>
<kwd lng="es"><![CDATA[homeostasia de la glucosa]]></kwd>
<kwd lng="en"><![CDATA[diabetes therapy]]></kwd>
<kwd lng="en"><![CDATA[type 2 diabetes mellitus]]></kwd>
<kwd lng="en"><![CDATA[sodium glucose co-transporter]]></kwd>
<kwd lng="en"><![CDATA[type 2 inhibitors]]></kwd>
<kwd lng="en"><![CDATA[glucose homeostasis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Adiposopathy, diabetes mellitus, and primary prevention of atheroesclerotic coronary artery disease: treating &#8220;scik fat&#8221; through improving fat function with antidiabetes therapies]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bays]]></surname>
<given-names><![CDATA[HE]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Cardiol]]></source>
<year>2012</year>
<volume>110</volume>
<page-range>4B-12B</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Glucotoxicity and beta cell failure in type 2 diabetes mellitus]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaiser]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Leibowitz]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Nesher]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Pediatr Endocrinol Metab]]></source>
<year>2003</year>
<volume>16</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>5-22</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Del Prato]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabet Med]]></source>
<year>2009</year>
<volume>26</volume>
<page-range>1185-92</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reichard]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Nilsson]]></surname>
<given-names><![CDATA[BY]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenqvist]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<source><![CDATA[N Eng J Med]]></source>
<year>1993</year>
<volume>329</volume>
<page-range>3004-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The effect of intensive treatment of diabetes me-llitus on the development and progression of long-term complications in insulin-dependent diabetes mellitus The Diabetes Control and Complications Trial Research Group]]></article-title>
<collab>Diabetes Control and Complications Trial Research group</collab>
<source><![CDATA[N Eng J Med]]></source>
<year>1993</year>
<volume>329</volume>
<page-range>977-86</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Intensive insulin therapy prevents the progression of diabetic microvas-cular complications in Japanese patients with non-insulin dependent diabetes mellitus a randomized prospective 6-year study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ohkubo]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kishikawa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Araki]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Res Clin Pract]]></source>
<year>1995</year>
<volume>28</volume>
<page-range>103-17</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKDPS) Group]]></article-title>
<collab>UK Prospective Diabetes Study Group</collab>
<source><![CDATA[Lancet]]></source>
<year>1998</year>
<volume>352</volume>
<page-range>837-53</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) UK Prospective Diabetes Study (UKDPS) Group]]></article-title>
<collab>UK Prospective Diabetes Study Group</collab>
<source><![CDATA[Lancet]]></source>
<year>1998</year>
<volume>352</volume>
<page-range>854-65</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35) prospective observational study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stratton]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Adler]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Neil]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
</person-group>
<source><![CDATA[BMJ]]></source>
<year>2000</year>
<volume>321</volume>
<page-range>405-12</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[MacMahon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chalmers]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2008</year>
<volume>358</volume>
<page-range>2560-72</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Intensive glucose control improves kidney outcomes in patients with type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perkovic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Heerspink]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Chalmers]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Kidney Int]]></source>
<year>2013</year>
<volume>83</volume>
<page-range>517-23</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Intensive glucose control and macrovascular outcomes in type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turnbull]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Abraira]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetologia]]></source>
<year>2009</year>
<volume>52</volume>
<page-range>2288-98</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes meta-analysis of randomized controlled trials]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boussageon]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bejan-Angoulvant]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Saaditan-Elahi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[BMJ]]></source>
<year>2011</year>
<volume>343</volume>
<page-range>d6898</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Glucose control and cardiovascular outcomes in individuals with diabetes mellitus lessons learned from the megatrials]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Avitabile]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Banka]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
</person-group>
<source><![CDATA[Heart Fail Clin]]></source>
<year>2012</year>
<volume>8</volume>
<page-range>513-22</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Standards of medical care in diabetes 2014]]></article-title>
<collab>American Diabetes Association</collab>
<source><![CDATA[Diabetes Care]]></source>
<year>2014</year>
<volume>37</volume>
<page-range>s14-80</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Management of hyperglycemia in type 2 diabetes a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inzucchi]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Bergenstal]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Buse]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Care]]></source>
<year>2012</year>
<volume>35</volume>
<page-range>1364-79</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Global guidelines for type 2]]></article-title>
<collab>International Diabetes Federation</collab>
<source><![CDATA[Diabetes]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus therapeutics implications]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gerich]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<source><![CDATA[Diab Med]]></source>
<year>2010</year>
<volume>27</volume>
<page-range>136-42</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Molecular physiology of sodium glucose cotransporters]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hediger]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Rhoads]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
</person-group>
<source><![CDATA[Physiol Rev]]></source>
<year>1994</year>
<volume>74</volume>
<page-range>993-1026</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Biology of human sodium glucose transporters]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wrigth]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Loo]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Hirayama]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
</person-group>
<source><![CDATA[Physiol Rev]]></source>
<year>2011</year>
<volume>91</volume>
<page-range>733.94</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Renal handling of organic solutes In: Brenner BM, editor. Brenner and Rector&amp;apos;s The Kidney]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moe]]></surname>
<given-names><![CDATA[OW]]></given-names>
</name>
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Palacin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Philadelphia: Saunders Elsevier;]]></source>
<year>2008</year>
<page-range>214-47</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Glucose transport in the renal tubule In: Windhager, editor. Handbook of physiology]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silverman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Turner]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<source><![CDATA[New York: Oxford University Press;]]></source>
<year>1992</year>
<page-range>217-38</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetics subjects]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mogensen]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
</person-group>
<source><![CDATA[Scan J Clin Lab Invest]]></source>
<year>1971</year>
<volume>28</volume>
<page-range>101-9</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Glucose transporters in human renal proximal tubular cells isolated from urine of patients with non-insulin-dependent diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rahmoune]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[Ward]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes]]></source>
<year>2005</year>
<volume>54</volume>
<page-range>3427-34</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vestri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Okamoto]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[de Freitas]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
</person-group>
<source><![CDATA[J Membr Biol]]></source>
<year>2001</year>
<volume>82</volume>
<page-range>105-12</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[From victim to ally the kidney as an emerging target for the treatment of diabetes mellitus]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bays]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr Med Res Opin]]></source>
<year>2009</year>
<volume>25</volume>
<page-range>671-81</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rossetti]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Giaccari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[DeFronzo]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes]]></article-title>
<collab>Glucose toxicity</collab>
<source><![CDATA[Care]]></source>
<year>1990</year>
<volume>13</volume>
<page-range>610-30</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Phlorizin a review]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eherenkranz]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[NG]]></given-names>
</name>
<name>
<surname><![CDATA[Kahn]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Roth]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Metab Res Rev]]></source>
<year>2005</year>
<volume>21</volume>
<page-range>31-8</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Apple trees to sodium glucose co-transporter inhibitors a review of SGLT2 inhibition]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Withe Jr]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Diabetes]]></source>
<year>2010</year>
<volume>28</volume>
<page-range>5-10</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine, in vitro]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alvarado]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Crane]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
</person-group>
<source><![CDATA[Biochim Biophys Acta]]></source>
<year>1962</year>
<volume>56</volume>
<page-range>170-2</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rossetti]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Shulman]]></surname>
<given-names><![CDATA[GI]]></given-names>
</name>
<name>
<surname><![CDATA[Papachristou]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[DeFronzo]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Invest]]></source>
<year>1987</year>
<volume>78</volume>
<page-range>1510-5</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rossetti]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Shulman]]></surname>
<given-names><![CDATA[GI]]></given-names>
</name>
<name>
<surname><![CDATA[Zawalich]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[DeFronzo]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Invest]]></source>
<year>1987</year>
<volume>80</volume>
<page-range>1037-44</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[T1095, an inhibitor of Na+-glucose contransporters, may provide a novel approach to treating diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oku]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ueta]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Arakawa]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes]]></source>
<year>1999</year>
<volume>48</volume>
<page-range>1794-800</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin a randomized double-blind placebo-controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gross]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Pieters]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bastein]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[List]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet]]></source>
<year>2010</year>
<volume>375</volume>
<page-range>2223-33</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nauck]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Del Prato]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Meier]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Care]]></source>
<year>2011</year>
<volume>34</volume>
<page-range>2015-22</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilding]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Woo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Rohwedder]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sugg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Parihk]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[List]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Woo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Morales]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Fiedorek]]></surname>
<given-names><![CDATA[FT]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Care]]></source>
<year>2009</year>
<volume>32</volume>
<page-range>650-7</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers applicability of a novel insulin-independent treatment]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilding]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Norwood]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[T&aposJoen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bastien]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[List]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Fiedorek]]></surname>
<given-names><![CDATA[FT]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Care]]></source>
<year>2009</year>
<volume>32</volume>
<page-range>1656-62</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effecty of da-pagliflozin in patients with type 2 diabetes who have inadequate glycemic control with glimepiride a randomized, 24-week, double blinded, active-controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strojek]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yoon]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Hruba]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Elze]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2011</year>
<volume>13</volume>
<page-range>928-38</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosentrock]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vico]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Salsali]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[List]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Care]]></source>
<year>2012</year>
<volume>35</volume>
<page-range>1473-8</page-range></nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Long-term efficacy of dapagloflozin in patients with type 2 diabetes mellitus receiving high doses of insulin a randomized trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilding]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Woo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Soler]]></surname>
<given-names><![CDATA[NG]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Intern Med]]></source>
<year>2012</year>
<volume>156</volume>
<page-range>405-15</page-range></nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effect of dapagliflozin on renal function]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ptaszynska]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chalamandaris]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Sugg]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Johnsson]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Parikh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[List]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes]]></source>
<year>2012</year>
<numero>^s61</numero>
<issue>^s61</issue>
<supplement>61</supplement>
<page-range>A283</page-range></nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stenlof]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Cefalu]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2013</year>
<volume>15</volume>
<page-range>372-82</page-range></nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Dose ranging effects of canagliflozin, a sodium- glucose co-transporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenstock]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Aggarw]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Polidori]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Care]]></source>
<year>2012</year>
<volume>35</volume>
<page-range>1232-8</page-range></nlm-citation>
</ref>
<ref id="B45">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Canagliflozin, a sodium-glucose co-transporter 2 inhibitor, improves glycaemnia in subjects with type 2 diabetes inadequately controlled with metformin plus sulphonylurea]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilding]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mathieu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Deng]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetologia]]></source>
<year>2012</year>
<volume>55</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S315</page-range></nlm-citation>
</ref>
<ref id="B46">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU) 52 week results from a randomized, double-blind, phase 3 non inferiority trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cefalu]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
<name>
<surname><![CDATA[Leiter]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Yoon]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet]]></source>
<year>2013</year>
<volume>382</volume>
<page-range>941-50</page-range></nlm-citation>
</ref>
<ref id="B47">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with met-formin and sulphonylurea a 52 week randomized trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scherthaner]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gross]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenstock]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Care]]></source>
<year>2013</year>
<volume>36</volume>
<page-range>2508-15</page-range></nlm-citation>
</ref>
<ref id="B48">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yale]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Bakris]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cariou]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2013</year>
<volume>15</volume>
<page-range>463-73</page-range></nlm-citation>
</ref>
<ref id="B49">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus a randomized trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bode]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Stenlöf]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Usiskin]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Hosp Pract (1995)]]></source>
<year>2013</year>
<volume>41</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>72-84</page-range></nlm-citation>
</ref>
<ref id="B50">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy and safety of canagliflozin (CANA) in subjects with type 2 diabetes mellitus (T2DM) on metformin (MET) and pioglitazone (PIO) over 52 weeks]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Forst]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Guthrie]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Goldenberg]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes]]></source>
<year>2013</year>
<volume>62</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>A284</page-range></nlm-citation>
</ref>
<ref id="B51">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Devinevi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Morrow]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hompesch]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2012</year>
<volume>14</volume>
<page-range>539-45</page-range></nlm-citation>
</ref>
<ref id="B52">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2) added-on insulin therapy ± oral agents in type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matthews]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Fulcher]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Perkovic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetologia]]></source>
<year>2012</year>
<volume>55</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S314</page-range></nlm-citation>
</ref>
<ref id="B53">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A phase IIb, randomized placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferranini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Seman]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Seewaldt-Becker]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hantel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2013</year>
<volume>15</volume>
<page-range>721-8</page-range></nlm-citation>
</ref>
<ref id="B54">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Empagliflozin monothe-rapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roden]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Weng]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Eilbracth]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet Diabetes Endocrinol]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B55">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy and safety of empagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor as add-on to metformin in type 2 diabetes with mild hyperglycaemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenstock]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Seman]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jelaska]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B56">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Safety and efficacy of empagliflozin as monotherapy or add-on to metformin in a 78-week open-label extension study in patients with type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Woerle]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ferranini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Berk]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Manunebo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pinnetti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Broedl]]></surname>
<given-names><![CDATA[UC]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes]]></source>
<year>2012</year>
<volume>61</volume>
<page-range>LB13</page-range></nlm-citation>
</ref>
<ref id="B57">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Empagliflo-zin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Häring]]></surname>
<given-names><![CDATA[HU]]></given-names>
</name>
<name>
<surname><![CDATA[Merker]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Seewaldt-Becker]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Care]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B58">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Empagliflozin as add-on to metformin for 24 weeks improves glycemic control in patients with type 2 diabetes (T2DM)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Häring]]></surname>
<given-names><![CDATA[HU]]></given-names>
</name>
<name>
<surname><![CDATA[Merker]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Seewaldt-Becker]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Weimer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Meinicke]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes]]></source>
<year>2013</year>
<volume>62</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>A282</page-range></nlm-citation>
</ref>
<ref id="B59">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kovacs]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Seshia]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Swallow]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B60">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Empagliflozin as add-on to basal insulin for 78 week improves glycemic control with weight loss in insulin. Treated type 2 diabetes (T2DM)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenstock, Jelaska]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Broedl]]></surname>
<given-names><![CDATA[UC]]></given-names>
</name>
<name>
<surname><![CDATA[Woerle]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes]]></source>
<year>2013</year>
<volume>62</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>A285</page-range></nlm-citation>
</ref>
<ref id="B61">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Härin]]></surname>
<given-names><![CDATA[HU]]></given-names>
</name>
<name>
<surname><![CDATA[Merker]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Seewaldt-Becker]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Care]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B62">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Safety, pharmacokinetic, and pharmacodynamics profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co transporter 2, in patients with type 2 diabetes mellitus]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schawartz]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Akinlade]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Klasen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Technol Ther]]></source>
<year>2011</year>
<volume>13</volume>
<page-range>1219-27</page-range></nlm-citation>
</ref>
<ref id="B63">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Ipragliflozin improved glycemic control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus: BRIGTHEN Study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kashiwagi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Takinami]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kazuta]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetologia]]></source>
<year>2011</year>
<volume>54</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S68</page-range></nlm-citation>
</ref>
<ref id="B64">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin a dose finding study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilding]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrannini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Wilpshaar]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Dhanjal]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2013</year>
<volume>15</volume>
<page-range>403-9</page-range></nlm-citation>
</ref>
<ref id="B65">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Ipragliflozin reduced HbA1c and body weight in Japanese type 2 diabetes patients who have inadequate glycaemic control on sulphonylurea or pioglitazone alone]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kashiwagi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Shiga]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Akiyama]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabeteologia]]></source>
<year>2012</year>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S302</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
